[go: up one dir, main page]

DK3380119T3 - Fmdv- og e2-fusionsproteiner og anvendelser deraf - Google Patents

Fmdv- og e2-fusionsproteiner og anvendelser deraf Download PDF

Info

Publication number
DK3380119T3
DK3380119T3 DK16813258.7T DK16813258T DK3380119T3 DK 3380119 T3 DK3380119 T3 DK 3380119T3 DK 16813258 T DK16813258 T DK 16813258T DK 3380119 T3 DK3380119 T3 DK 3380119T3
Authority
DK
Denmark
Prior art keywords
fmdv
fusion proteins
fusion
proteins
Prior art date
Application number
DK16813258.7T
Other languages
English (en)
Inventor
Jean-Christophe Audonnet
Frederic Reynard
Natalia Bomchil
Cecile Sigoillot-Claude
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Application granted granted Critical
Publication of DK3380119T3 publication Critical patent/DK3380119T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/135Foot- and mouth-disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16813258.7T 2015-11-23 2016-11-16 Fmdv- og e2-fusionsproteiner og anvendelser deraf DK3380119T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259043P 2015-11-23 2015-11-23
PCT/US2016/062367 WO2017091418A1 (en) 2015-11-23 2016-11-16 Fmdv and e2 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
DK3380119T3 true DK3380119T3 (da) 2021-11-15

Family

ID=57570585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16813258.7T DK3380119T3 (da) 2015-11-23 2016-11-16 Fmdv- og e2-fusionsproteiner og anvendelser deraf

Country Status (19)

Country Link
US (2) US9913891B2 (da)
EP (2) EP3380119B1 (da)
JP (2) JP6797206B2 (da)
KR (1) KR102153303B1 (da)
CN (1) CN108367067B (da)
AR (1) AR106792A1 (da)
AU (1) AU2016361305B2 (da)
BR (1) BR112018010494A8 (da)
CA (1) CA3006078A1 (da)
DK (1) DK3380119T3 (da)
ES (1) ES2899230T3 (da)
MA (3) MA49414A (da)
MX (1) MX382535B (da)
NZ (1) NZ743236A (da)
RU (1) RU2714428C2 (da)
TW (1) TWI744260B (da)
UY (1) UY36995A (da)
WO (1) WO2017091418A1 (da)
ZA (1) ZA201803390B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CA3094416A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Recombinant virus capable of stably expressing target proteins
CN109187993B (zh) * 2018-09-13 2020-06-16 中国农业科学院兰州兽医研究所 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) * 2019-01-24 2022-04-29 暨南大学 一种功能性微藻固定化材料的制备方法及其应用
CN114423779B (zh) * 2019-06-28 2024-07-02 株式会社准绳生命科学 口蹄疫病毒疫苗组合物
CN115925907B (zh) * 2022-09-19 2025-08-05 北京田园奥瑞生物科技有限公司 一种羊口蹄疫纳米抗体及其在精液保藏检测中的应用
CN119505021B (zh) * 2025-01-20 2025-04-18 内蒙古和讯生物科技有限公司 一种重复结构单元重组蛋白cpE2及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
WO1996034109A1 (en) 1995-04-25 1996-10-31 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
UA84024C2 (ru) 2003-07-24 2008-09-10 Мериал Лимитед Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"
PL1773387T3 (pl) 2004-06-25 2013-10-31 Merial Inc Rekombinanty wirusa ospy ptasiej wyrażające geny wirusa pryszczycy
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP2316480A1 (en) * 2006-03-17 2011-05-04 Indian Immunologicals Ltd Chimeric tymovirus-like particles
CN101293098A (zh) * 2007-04-28 2008-10-29 北京迪威华宇生物技术有限公司 一种重组牛o型口蹄疫病毒融合蛋白疫苗
WO2011031850A1 (en) 2009-09-10 2011-03-17 Merial Limited New vaccine formulations comprising saponin-containing adjuvants
NZ702145A (en) * 2010-03-12 2016-03-31 Merial Inc Bluetongue virus recombinant vaccines and uses thereof
RU2467014C2 (ru) * 2010-12-06 2012-11-20 Учреждение Российской академии наук Центр "Боинженерия" РАН Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) * 2012-11-16 2015-07-22 유나이티드 바이오메디칼 인크. 구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
WO2014089009A1 (en) * 2012-12-05 2014-06-12 Thevax Genetics Vaccine Co., Ltd. Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
CN103305542B (zh) * 2013-06-25 2015-03-11 江苏省农业科学院 一种重组噬菌体双表达载体及应用
EP3054971B1 (en) * 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CN103933581A (zh) * 2014-05-04 2014-07-23 贵州大学 一种基于csf-fmd二联基因工程疫苗的制备方法
CA2962225A1 (en) 2014-09-23 2016-03-31 Merial, Inc. Fmdv recombinant vaccines and uses thereof

Also Published As

Publication number Publication date
JP2019500409A (ja) 2019-01-10
RU2714428C2 (ru) 2020-02-14
AR106792A1 (es) 2018-02-21
RU2018122755A3 (da) 2019-12-26
US20180169216A1 (en) 2018-06-21
BR112018010494A2 (pt) 2018-11-13
MA42640B1 (fr) 2021-06-30
TWI744260B (zh) 2021-11-01
MA42640A1 (fr) 2019-05-31
ES2899230T3 (es) 2022-03-10
CN108367067A (zh) 2018-08-03
WO2017091418A1 (en) 2017-06-01
MX382535B (es) 2025-03-13
HK1258695A1 (en) 2019-11-15
KR20180084995A (ko) 2018-07-25
NZ743236A (en) 2019-12-20
EP3380119A1 (en) 2018-10-03
US10363300B2 (en) 2019-07-30
UY36995A (es) 2017-06-30
AU2016361305B2 (en) 2020-02-06
US9913891B2 (en) 2018-03-13
MA43310A (fr) 2021-04-28
AU2016361305A1 (en) 2018-06-28
KR102153303B1 (ko) 2020-09-09
ZA201803390B (en) 2019-03-27
US20170143819A1 (en) 2017-05-25
JP2020203890A (ja) 2020-12-24
BR112018010494A8 (pt) 2019-02-26
EP3380119B1 (en) 2021-08-25
JP6797206B2 (ja) 2020-12-09
RU2018122755A (ru) 2019-12-26
CN108367067B (zh) 2022-05-03
MX2018006347A (es) 2019-02-20
MA49414A (fr) 2020-04-22
EP3539566A1 (en) 2019-09-18
CA3006078A1 (en) 2017-06-01
TW201726708A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
IL262652A (en) Gdf15 fusion proteins and uses thereof
IL254165A0 (en) Immunomodulatory fusion proteins and uses thereof
DK3292141T3 (da) Fusionsproteiner
IL255697A (en) Compositions and methods for tcr reprogramming using fusion proteins
ZA201801640B (en) Gitrl fusion proteins and uses thereof
IL246921B (en) Binding proteins and methods of use thereof
DK3280727T3 (da) Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
IL254516A0 (en) Proteins specific for cd137
DK4234581T3 (da) Terapeutiske antistoffer og deres anvendelse
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
HRP20190028T1 (hr) Interleukin-2 fuzijski proteini i njihove primjene
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3107562T3 (da) P97-ids-fusionsproteiner
DK3322734T3 (da) Multivalente og multispecifikke DR5-bindende fusionsproteiner
DK3380119T3 (da) Fmdv- og e2-fusionsproteiner og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
EP3344278A4 (en) INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
DK3290441T3 (da) Rgma-bindingsprotein og anvendelse deraf
EP3738976C0 (en) IL-17A-BINDING FUSION PROTEIN